Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 41 of 45

Conclusions (2 of 4)

Indirect comparisons reveal potential differences in effectiveness of the biologic disease-modifying anti-rheumatic drugs (DMARDs) in treating rheumatoid arthritis, but the analysis should be interpreted with caution.

Combining biologic DMARDs provides no additional benefits and increases the risk of serious adverse effects.

In patients with inadequate disease control, biologic DMARDs used in combination with methotrexate (MTX) offer greater relief than monotherapy with either MTX or a biologic DMARD without increasing treatment discontinuation due to adverse effects.